Ceres Sells Forage Sorghum in Puerto Rico

- Island dairies plant commercial evaluations of Ceres' improved forage sorghum hybrids
- Subtropical conditions similar to other international markets

THOUSAND OAKS, Calif., Sept. 3, 2015 -- Ceres, Inc. (CERE), an agricultural biotechnology company, today announced that it has expanded commercial evaluations of its improved forage hybrids in Puerto Rico. Growers and dairies on the island territory have planted multiple, commercial-scale evaluations of Ceres' seed products in order to diversify their supply of feed and forage.

Milk production is the single largest sector of Puerto Rico's agricultural economy. Due in part to limits on land and resources, the sector includes highly sophisticated dairy businesses, which optimize supply chains and feed rations to maximize production and efficiency, including locally sourced feed and forage crops.

BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health

NESS ZIONA, Israel, September 2, 2015 -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced the intent of the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to launch a new phase 2 trial to be held in the United States in the 2015-16 timeframe. The trial will examine the use of BiondVax's universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would be administered several weeks before a pandemic vaccine. The trial will be a collaboration between BiondVax and the National Institute of Allergy and Infectious Diseases.

The trial will assess the ability of M-001 in humans to serve as a pandemic primer to the H7N9 avian pandemic vaccine, by enhancing protective immunity to these highly pathogenic avian influenza H7 strains. It will also look to strengthen previous clinical and pre-clinical findings on M-001 priming capacity to other seasonal and pandemic strains.

Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain

– Novel mu-opioid receptor modulator TRV130 achieved primary endpoint –
– Superior safety and tolerability profile of TRV130 compared to morphine –
– Company to host conference call at 5:00 PM EDT –

KING OF PRUSSIA, Pa.-- Trevena, Inc. (TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery. The study achieved its primary endpoint of statistically greater pain reduction than placebo over 24 hours. In addition, TRV130 was superior to morphine in pre-specified secondary measures, exhibiting significantly reduced nausea, vomiting, and hypoventilation events.